EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block

Jason Liu iD, Arya Amini iD, Ameish Govindarajan iD, Tariq Abuali, Isa Mambetsariev iD, Erminia Massarelli iD, Victoria Villaflor, Miguel Villalona-Calero iD, Howard West iD, Terence Williams iD, Ravi Salgia iD

JCO Precision Oncology · 2023

DOI: 10.1200/po.22.00445 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Jason Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Molecular Targeted Therapy, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE With increased adoption of next-generation sequencing, tailored therapy on the basis of molecular status is being delivered for patients with early-stage resectable non–small-cell lung cancer (NSCLC). The purpose of this narrative review was to focus on recent developments of targeted therapies in the adjuvant and neoadjuvant/adjuvant setting for early-stage disease. METHODS A systematic search of the MEDLINE/PubMed database was performed, focusing on studies published within the past 10 years. Our search queried “early-stage NSCLC (AND) tyrosine kinase inhibitor (TKI; OR) epidermal growth factor receptor (EGFR; OR) anaplastic lymphoma kinase ( ALK)” and was limited only to prospective and ongoing studies. RESULTS Most studies examining the benefit of targeted therapies in early-stage resectable NSCLC have been for EGFR-TKIs in the adjuvant setting. Currently, only one study, the ADAURA trial of adjuvant osimertinib, has demonstrated an overall survival benefit with the use of an EGFR-TKI in the adjuvant setting. Future work to build on the success of the ADAURA trial is focused on determining the optimal duration of targeted therapies and using biomarkers, such as circulating tumor DNA, to risk-stratify patients and guide maintenance targeted therapy duration. CONCLUSION The results of several ongoing studies are eagerly awaited regarding the use of targeted therapies in the neoadjuvant/adjuvant setting and for more uncommon or rare mutations such as ALK, ROS proto-oncogene 1, rearranged during transfection, mesenchymal-epithelial transition factor, and B-Raf proto-oncogene V600E. The treatment landscape for early-stage NSCLC harboring actionable mutations is likely to shift dramatically in the upcoming decade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMolecular Targeted TherapyProtein Kinase InhibitorsHumansProto-Oncogene MasErbB ReceptorsNeoplasm StagingNeoadjuvant Therapy

Substanzen

Proto-Oncogene MasMAS1 protein, humanProtein Kinase InhibitorsErbB Receptors

Autor:innen und Institutionen

  • Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA.
  • Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA.

ORCID-Profile: Jason Liu, Arya Amini, Ameish Govindarajan, Isa Mambetsariev, Erminia Massarelli, Miguel Villalona-Calero, Howard West, Terence Williams, Ravi Salgia

Zitieren

APA

Liu, J., Amini, A., Govindarajan, A., Abuali, T., Mambetsariev, I., Massarelli, E., Villaflor, V., Villalona-Calero, M., West, H., Williams, T., & Salgia, R. (2023). Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block. JCO Precision Oncology. https://doi.org/10.1200/po.22.00445

Vancouver

Liu J, Amini A, Govindarajan A, Abuali T, Mambetsariev I, Massarelli E, et al. Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block. JCO Precision Oncology. 2023. doi:10.1200/po.22.00445

BibTeX
@article{Liu2023,
  author = {Liu, Jason and Amini, Arya and Govindarajan, Ameish and Abuali, Tariq and Mambetsariev, Isa and Massarelli, Erminia and Villaflor, Victoria and Villalona-Calero, Miguel and West, Howard and Williams, Terence and Salgia, Ravi},
  title = {Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.22.00445}
}
Kostenlos starten →